Progestogen maintenance therapy for prolongation of pregnancy after an episode of preterm labour: a systematic review and meta-analysis

• Breuking S.H.
• De Ruigh A.A.
• Hermans F.J.R.
• Schuit Е.
• Combs C.A.
• de Tejada B.M.
• Oudijk M.A.
• Mol B.W.
• Pajkrt E.

Abstract

Background. Evidence for progestogen maintenance therapy after an episode of preterm labour (PTL) is contradictory.

Objectives. To assess effectiveness of progestogen maintenance therapy after an episode of PTL.

Search Strategy. An electronic search in Central Cochrane, Ovid Embase, Ovid Medline and clinical trial databases was performed.

Selection criteria. Randomised controlled trials (RCT) investigating women between 16⁺⁰ and 37⁺⁰ weeks of gestation with an episode of PTL who were treated with progestogen maintenance therapy compared with a control group.

Data collection and analysis. Systematic review and meta-analysis were conducted. The primary outcome was latency time in days. Secondary neonatal and maternal outcomes are consistent with the core outcome set for preterm birth studies. Studies were extensively assessed for data trustworthiness (integrity) and risk of bias.

Main results. Thirteen RCT (1722 women) were included. Progestogen maintenance therapy demonstrated a longer latency time of 4.32 days compared with controls (mean difference [MD] 4.32, 95% CI 0.40–8.24) and neonates were born with a higher birthweight (MD 124.25 g, 95% CI 8.99–239.51). No differences were found for other perinatal outcomes. However, when analysing studies with low risk of bias only (five RCT, 591 women), a significantly longer latency time could not be shown (MD 2.44 days; 95% CI −4.55 to 9.42).

Conclusion. Progestogen maintenance therapy after PTL might have a modest effect on prolongation of latency time. When analysing low risk of bias studies only, this effect was not demonstrated. Validation through further research, preferably by an individual patient data meta-analysis is highly recommended.

Keywords:arrested preterm labour; meta-analysis; preterm birth; preterm labour; progesterone, progestogen; threatened preterm birth; threatened preterm labour; tocolysis

References

1. Blencowe H., Cousens S., Oestergaard M.Z., Chou D., Moller A.B., Narwal R., et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012; 379 (9832): 2162–72.

2. Purisch S.E., Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol. 2017; 41 (7): 387–91.

3. McPheeters M.L., Miller W.C., Hartmann K.E., Savitz D.A., Kaufman J.S., Garrett J.M., et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol. 2005; 192 (4): 1325–9.

4. Hermans F.J.R., Bruijn M.M.C., Vis J.Y., Wilms F.F., Oudijk M.A., Porath M.M., et al. Risk stratification with cervical length and fetal fibronectin in women with threatened preterm labor before 34 weeks and not delivering within 7 days. Acta Obstet Gynecol Scand. 2015; 94 (7): 715–21.

5. van Vliet E.O.G., Nijman T.A.J., Schuit E., Heida K.Y., Opmeer B.C., Kok M., et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016; 387 (10 033): 2117–24.

6. Han S., Crowther C.A., Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev. 2013; 5: CD000940.

7. Naik Gaunekar N., Raman P., Bain E., Crowther C.A. Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev. 2013; 10: CD004071.

8. Martinez de Tejada B., Karolinski A., Ocampo M.C., Laterra C., Hosli I., Fernandez D., et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG. 2015; 122 (1): 80–91.

9. Dodd J.M., Crowther C.A., Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev. 2012; 12: CD003927.

10. van Vliet E., Dijkema G.H., Schuit E., Heida K.Y., Roos C., van der Post J., et al. Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis. BJOG. 2016; 123 (11): 1753–60.

11. Romero R., Conde-Agudelo A., Da Fonseca E., O’Brien J.M., Cetingoz E., Creasy G.W., et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol. 2018; 218 (2): 161–80.

12. Romero R., Nicolaides K., Conde-Agudelo A., Tabor A., O’Brien J.M., Cetingoz E., et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and meta-analysis of individual patient data. Am J Obstet Gynecol. 2012; 206 (2): 124.e1–19.

13. Romero R., Stanczyk F.Z. Progesterone is not the same as 17alpha-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013; 208 (6): 421–6.

14. Meis P.J., Klebanoff M., Thom E., Dombrowski M.P., Sibai B., Moawad A.H., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003; 348 (24): 2379–85.

15. Romero R. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. Ultrasound Obstet Gynecol. 2007; 30 (5): 675–86.

16. Hirota Y., Cha J., Dey S.K. Revisiting reproduction: prematurity and the puzzle of progesterone resistance. Nat Med. 2010; 16 (5): 529–31.

17. Saccone G., Suhag A., Berghella V. 17-Alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and meta-analysis of randomized trials. Am J Obstet Gynecol. 2015; 213 (1): 16-22.

18. Suhag A., Saccone G., Berghella V. 17-Alpha-hydroxyprogesterone caproate for maintenance tocolysis: a meta-analysis of randomized trials. Am J Obstet Gynecol. 2015; 1: S372.

19. Eke A.C., Chalaan T., Shukr G., Eleje G.U., Okafor C.I. A systematic review and meta-analysis of progestogen use for maintenance tocolysis after preterm labor in women with intact membranes. Int J Gynaecol Obstet. 2016; 132 (1): 11-6.

20. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62 (10): 1006-12.

21. Bordewijk E.M., Wang R., Askie L.M., Gurrin L.C., Thornton J.G., van Wely M., et al. Data integrity of 35 randomised controlled trials in women’ health. Eur J Obstet Gynecol Reprod Biol. 2020; 249: 72-83.

22. Li W., Bordewijk E.M., Mol B.W. Assessing research misconduct in randomized controlled trials. Obstet Gynecol. 2021; 138 (3): 338-47.

23. Sterne J.A.C., Savovic J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898.

24. Van’t Hooft J., Cuijpers C., Schneeberger C., Van Der Lee J.H., Opmeer B.C., Steenis L., et al. Preventing preterm birth with progesterone in women with short cervical length, outcomes in children at 24 months of age. Am J Obstet Gynecol. 2017; 216 (1 suppl 1): S492.

25. Bell R.S. Neonatal necrotizing enterocolitis. N Engl J Med. 1970; 283 (3): 153-4.

26. Mishra G.S., Inamdar S.A. Role of micronized progesterone in maintenance therapy following arrested preterm labor: a randomised controlled trial. Int J Reprod Contracept Obstet Gynecol. 2014; 3 (4): 1050-5.

27. Hyett J., Asadi N., Zare Khafri M., Vafaei H., Kasraeian M., Salehi A., et al. The use of vaginal progesterone as a maintenance therapy in women with arrested preterm labor: a double-blind placebo-randomized controlled trial. J Matern Fetal Neonatal Med. 2020; 35 (6): 1134-40.

28. Chawanpaiboon S., Pimol K., Sirisomboon R. Comparison of success rate of nifedipine, progesterone, and bed rest for inhibiting uterine contraction in threatened preterm labor. J Obstet Gynaecol Res. 2011; 37 (7): 787-91.

29. Ez E.L.-A., Mahmood M., Hamsa R., Amal H. Efficacy of vaginal progesterone for maintenance tocolysis: a recent trend in the management of arrested preterm labour. Med J Cairo Univ. 2009; 77 (2): 99-104.

30. Abdelgaied A.M., Dawood R.M., Nofal A.M., El-Sisi E.F. Comparison study between nifedipine and progesterone as maintenance tocolysis after arrested preterm labor. Menoufia Med J. 2019; 32: 458.

31. Lotfalizadeh M., Ghomian N., Reyhani A. The effects of progesterone therapy on the gestation length and reduction of neonatal complications in patients who had received tocolytic therapy for acute phase of preterm labor. Iran Red Crescent Med J. 2013; 15 (10): e7947.

32. Gargari S.S., Habibolahi M., Zonobi Z., Khani Z., Sarfjoo F.S., Robati A.K., et al. Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial. ISRN Obstet Gynecol. 2012; 2012: 607906.

33. Sharami S.H., Zahiri Z., Shakiba M., Milani F. Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo-controlled double-blind trial. Int J Fertil Steril. 2010; 4 (2): 45-50.

34. Regmi M.C., Rijal P., Agrawal A., Uprety D. Progesterone for prevention of recurrent preterm labor after arrested preterm labor - a randomized controlled trial. Gynecol Obstet. 2012; 2 (4): 125.

35. Ashraf B. Efficacy and safety of oral nifedipine with or without vaginal progesterone in the management of threatened preterm labor. Int J Reprod Biomed. 2019; 17 (9): 629-36.

36. Mohammad H.F., Abdel-Megeed A.-M.I., Alhady S.M. Effect of vaginal progesterone after tocolytic therapy on latency period in threatened preterm labor. J Egypt Soc Gynaecol Obstet. 2014; 40: 813-7.

37. Thongchan S., Phupong V. Oral dydrogesterone as an adjunctive therapy in the management of preterm labor: a randomized, double blinded, placebo-controlled trial. BMC Pregnancy Childbirth. 2021; 21 (1): 90.

38. Sirisangwon R., Phupong V. Vaginal progesterone supplementation in the management of preterm labor: a randomized controlled trial. Matern Child Health J. 2021; 25 (7): 1102-9.

39. Areeruk W., Phupong V. A randomized, double blinded, placebo controlled trial of oral dydrogesterone supplementation in the management of preterm labor. Sci Rep. 2016; 6: 20638.

40. Hafeez S., Khan B., Khan M., Syed S.Z., Waheed F., Mustafa R., et al. Is vaginal progesterone more effective to treat threatened preterm labour than oral nifedipine? Pak J Med Health Sci. 2022; 16 (9): 240-2.

41. Alizadeh F., Mahmoudinia M., Mirteimoori M., Pourali L., Niroumand S. Comparison of oral dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth. BMC Pregnancy Childbirth. 2022; 22 (1): 167.

42. Lotfalizadeh M.K.Z., Najafi M.N. Comparison of the duration of pregnancy in administration of progesterone suppository and duphaston tablet in pregnant women with preterm labor after stopping delivery process. Iran J Obstet Gynecol Infertil. 2019; 22 (10): 1-11.

43. Arikan I., Barut A., Harma M., Harma I.M. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest. 2011; 72 (4): 269-73.

44. Facchinetti F., Paganelli S., Comitini G., Dante G., Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007; 196 (5): 453.e1-4.

45. Facchinetti F., Vergani P., Di Tommaso M., Marozio L., Acaia B., Vicini R., et al. Progestogens for maintenance tocolysis in women with a short cervix: a randomized controlled trial. Obstet Gynecol. 2017; 130 (1): 64-70.

46. Kashanian M., KaramiAbd T., Sheikhansari N., AminiMoghaddam S., Jangjoo S. Efficacy of daily rectal micronized progesterone for prevention of preterm delivery: a randomized clinical trial. J Matern Fetal Neonatal Med. 2020; 35 (1): 122-8.

47. Briery C.M., Klauser C.K., Martin R.W., Magann E.F., Chauhan S.P., Morrison J.C. The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial. J Matern Fetal Neonatal Med. 2014; 27 (18): 1892-6.

48. Palacio M., Cobo T., Antolin E., Ramirez M., Cabrera F., Mozo de Rosales F., et al. Vaginal progesterone as maintenance treatment after an episode of preterm labour (PROMISE) study: a multicentre, double-blind, randomised, placebo-controlled trial. BJOG. 2016; 123 (12): 1990-9.

49. Wood S., Rabi Y., Tang S., Brant R., Ross S. Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis. BMC Pregnancy Childbirth. 2017; 17 (1): 258.

50. Rozenberg P. Is universal screening for cervical length among singleton pregnancies with no history of preterm birth justified? J Gynecol Obstet Biol Reprod. 2016; 45 (10): 1337-45.

51. Frey H.A., Stout M.J., Abdelwahab M., Tuuli M.G., Woolfolk C., Shamshirsaz A.A., et al. Vaginal progesterone for preterm birth prevention in women with arrested preterm labor. J Matern Fetal Neonatal Med. 2022; 35 (25): 8160-8.

52. Areia A., Fonseca E., Moura P. Progesterone use after successful treatment of threatened pre-term delivery. J Obstet Gynaecol. 2013; 33 (7): 678-81.

53. Choudhary M., Suneja A., Vaid N.B., Guleria K., Faridi M.M. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet. 2014; 126 (1): 60-3.

54. Borna S., Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008; 48 (1): 58-63.

55. Rozenberg P., Chauveaud A., Deruelle P., Capelle M., Winer N., Desbriere R., et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol. 2012; 206 (3): 206.e1-9.

56. Venetis C., d’Hooghe T., Barnhart K.T., Bossuyt P.M.M., Mol B.W.J. Methodologic considerations in randomized clinical trials in reproductive medicine. Fertil Steril. 2020; 113 (6): 1107-12.

57. Dodd J.M., Jones L., Flenady V., Cincotta R., Crowther C.A. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev. 2013; 7: CD004947.

58. Matsui D. Adherence with drug therapy in pregnancy. Obstet Gynecol Int. 2012; 2012: 796590.

59. Suhag A., Saccone G., Berghella V. Vaginal progesterone for maintenance tocolysis: a meta-analysis of randomized trials. Am J Obstet Gynecol. 2015; 1: S137-8.

60. Monari F., Chiossi G., Gargano G., Ballarini M., Baronciani D., Coscia A., et al. Delivery indication matters for perinatal outcomes in late preterm newborns. J Matern Fetal Neonatal Med. 2022; 35 (25): 8257-66.

61. Dodd J.M., Grivell R.M., O’Brien C.M., Dowswell T., Deussen A.R. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev. 2019; 11 (11): CD012024.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)